Modality
ERT
MOA
MALT1i
Target
VEGF
Pathway
Cell Cycle
LGS
Development Pipeline
Preclinical
~Nov 2021
→ ~Feb 2023
Phase 1
~May 2023
→ ~Aug 2024
Phase 2
Nov 2024
→ Mar 2025
Phase 2Current
NCT03381223
1,742 pts·LGS
2024-11→2025-03·Not yet recruiting
1,742 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-03-121.1y agoPh3 Readout· LGS
Trial Timeline
2025
P2/3
Not yet…
Catalysts
Ph3 Readout
2025-03-12 · 1.1y ago
LGS
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03381223 | Phase 2/3 | LGS | Not yet recr... | 1742 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 |